Gilead's expansion beyond HIV therapies will surprise many investors.

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value.

Making a creative pharma campaign that earns recognition at the prestigious Cannes Lions Festival of Creativity is a beast. Gilead Sciences conquered the task with the help of some AI-generated ...

A group of AIDS activists obtained an R&D pact at the heart of a settlement between the U.S. government and Gilead Sciences ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences and Johnson & Johnson . TipRanks Welcomes a New ETF – NYSE:RANK. TipRanks has e ...

July 14 (Reuters) - Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants ...

Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2025 financial results and guidance will be released on Thursday, April 24, 2025 after ...

– Funding Will Reach Under-Resourced Communities Most Impacted by the HIV Epidemic and COVID-19 Pandemic – FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc., (Nasdaq: GILD) today announced ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Shares of Gilead Sciences Inc. GILD advanced 5.21% to $136.36 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.45% to ...

Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall ...